Compounds

1. A compound or a pharmaceutically acceptable salt thereof having the structure of Formula (I-4)

wherein

R 1 is selected from the group consisting of H, C 1-3 alkyl, and —C(O)—C 1-3 alkyl; and

R 2 and R 3 together with the carbon to which they are attached form a 4-, 5- or 6-membered saturated ring, which ring

optionally contains one heteroatom ring member selected from N or O, and

is optionally substituted with one substituent of -L-K, wherein

L is selected from the group consisting of C(O), CH 2 , and S(O) 2 , and

K is selected from the group consisting of C 1-3 alkyl, phenyl, and C 3-6 cycloalkyl;

or R 1 and R 2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated ring, which ring

optionally contains one or two additional heteroatom ring members independently selected from the group consisting of N, O, C(O), S, S(O), and S(O) 2 , and

is optionally substituted with one or more substituents independently selected from the group consisting of OH, halo, NR 1a R 1b , COOH, and —Y—R c , wherein

Y is absent or is selected from the group consisting of C(O), S(O) 2 , —C(O)—C(O)—, and CH 2 , and

R c is selected from the group consisting of

 C 1-5 alkyl optionally substituted with one or more substituents independently selected from the group consisting of NR 2a R 2b , C 3-6 cycloalkyl, and —COOH,

 C 1-3 haloalkyl,

 C 1-3 alkoxyl,

 NR 3a R 3b ,

 —(CH 2 ) p —C(O)—O—C 1-3 alkyl, wherein p is 1, 2, or 3 and the —(CH 2 ) p — is optionally substituted by one or more methyl,

 —(CH 2 ) q —C 3-6 cycloalkyl, wherein q is 1, 2, or 3, the cycloalkyl is optionally substituted with NR 4a R 4b , and the —(CH 2 ) q — is optionally substituted by one or more methyl, and

 heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of halo and NR 5a R 5b ,

wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , and R 5b are independently H or C 1-3 alkyl; and

R 3 is H;

each occurrence of R 4 is independently H or D;

X is absent or is selected from the group consisting of

—O—,

—NH—, and

—N(C 1-3 alkyl)-,

n is 1 or 2; or

X is —O—CH 2 -bicyclo[1.1.1]pentanyl-CH 2 —O— and n is 0; and

A is unsubstituted thiophenyl, or

A is

wherein

R 5 and R 9 are independently H or halo,

Z′ is N or CR 6 ,

Z is N or CR 8 ,

wherein R 6 and R 8 are independently selected from the group consisting of H, CN, halo, C 1-3 alkyl, C 1-3 haloalkyl, —S(O) 2 —C 1-3 alkyl and —S(O)—C 1-3 alkyl, and

V is CR 7 , wherein R 7 is -Q-(CH 2 ) m —W, wherein

Q is O, N, or CH 2 ,

m is 0 or 1, and

W is pyridyl, and

wherein said pyridyl is optionally substituted with one or more substituents independently selected from the group consisting of C 1-3 haloalkyl, CN, halo, and C 1-5 alkyl.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein

R 1 and R 2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated, unsubstituted ring, which ring contains one additional heteroatom ring member selected from the group consisting of N, O, and C(O); and

R 3 is H;

each R 4 is H;

X is O;

n is 1 or 2; and

A is

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 and R 2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated ring, which ring optionally contains one additional heteroatom ring member selected from the group consisting of N, O, and C(O), and R 3 is H.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 4 is H.

5. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein X is O.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein n is 1.

7. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is

wherein

R 5 and R 9 are independently H or F, and

R 6 and R 8 are independently selected from the group consisting of H, CN, and F, and

R 7 is —O—W.

8. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is

wherein

R 5 and R 9 are independently H or F, and

R 6 and R 8 are independently selected from the group consisting of H, CN, and F, and

R 7 is —O—W, wherein W is pyridyl, and said pyridyl is optionally substituted with one or more substituents independently selected from the group consisting of CF 3 and CH 3 .

9. The compound or a pharmaceutically acceptable salt thereof according to claim 1 having the structure of Formula (A-4),

wherein

R 1 and R 2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated ring, which ring contains one additional heteroatom ring member selected from the group consisting of N, O, and C(O), and which ring has no further substitution;

R 5 and R 9 are independently H or F;

R 6 and R 8 are independently selected from the group consisting of H or F; and

W 1 is pyridyl, wherein said pyridyl is optionally substituted with one or two substituents independently selected from the group consisting of CF 3 and CH 3 .

10. The compound or a pharmaceutically acceptable salt thereof according to claim 1 having the structure of Formula (A-5),

wherein

R 1 and R 2 together with the nitrogen and carbon to which they are attached form a 6-membered saturated ring, which ring contains one additional heteroatom ring member O and which ring has no further substitution;

R 5 and R 9 are independently H or F;

R 6 and R 8 are independently selected from the group consisting of H or F; and

W 1 is pyridyl, wherein said pyridyl is optionally substituted with one or two substituents independently selected from the group consisting of CF 3 and CH 3 .

11. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable excipient.

12. A method for treating neurodegeneration disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .

13. The method according to claim 12 , wherein the neurodegeneration disease is Alzheimer's disease.

14. A method for treating atherosclerosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .